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Original StudieS
Aims: To systematically review the effectiveness of preventative and thera-
peutic interventions for respiratory tract infections (RTIs) in people with 
Down’s syndrome.
Methods: Databases were searched for any published and ongoing studies 
of respiratory tract diseases in children and adults with Down’s syndrome. 
These databases were searched for controlled trials, cohort studies and con-
trolled before–after studies. Trial registries were searched for ongoing stud-
ies. Initially, all study types were included to provide a broad overview of 
the existing evidence base. However, those with a critical risk of bias were 
excluded using the Cochrane Risk of Bias tool.
Results: A total of 13,575 records were identified from which 5 studies 
fulfilled the eligibility criteria and 3 fulfilled our criteria for data extrac-
tion. One randomized controlled trial of moderate risk of bias compared 
zinc therapy with placebo. Outcome data were only reported for 50 (78%) 
children who presented with extreme symptoms; no benefit of zinc therapy 
was found. One non-randomized controlled trial with serious risk of bias 
included 26 children and compared pidotimod (an immunostimulant) with 
no treatment; pidotimod was associated with fewer upper RTI recurrences 
compared with no treatment (1.43 vs. 3.82). A prospective cohort study 
with moderate risk of bias compared 532 palivizumab treated children with 
233 untreated children and found that children treated with palivizumab had 
fewer respiratory syncytial virus-related hospitalization (23 untreated and 
8 treated), but the same number of overall RTI-related hospitalizations (73 
untreated and 74 treated) in the first 2 years of life.
Conclusions: The evidence base for the management of RTIs in people 
with Down’s syndrome is incomplete; current studies included children 
only and carry a moderate to serious risk of bias. Methodologic rigorous 
studies are warranted to guide clinicians in how best to prevent and treat 
RTIs in children with Down’s syndrome.
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(Pediatr Infect Dis J 2016;35:1075–1079)
Down’s syndrome, also known as trisomy 21, is amongst the commonest genetic conditions worldwide, with an incidence 
of 1 in 1000 live births in the United Kingdom.1 Despite advances 
in antenatal screening since the 1990s, the number of children born 
with Down’s syndrome in the United Kingdom has remained stable.2
Discrete immune deficiencies, morphologic variations of the 
airways, generalized hypotonia and swallowing dysfunction predis-
pose children with Down’s syndrome to frequent and more severe 
respiratory tract infections (RTIs).3–7 One in 3 of all hospitaliza-
tion of children with Down’s syndrome less than 3 years of age are 
caused by RTIs, with 80% occurring before 2 years of age.8,9
Children with Down’s syndrome on average spend 2–3 times 
more time in hospital than those without Down’s syndrome.4,10 In 
children with Down’s syndrome, up to the age of 18, RTIs are the 
second leading cause of death. It is therefore important that effec-
tive interventions to prevent and treat these infections are devel-
oped. A number of preventive interventions are commonly prac-
ticed and believed to be of benefit including use of prophylactic 
antibiotics, respiratory syncytial virus (RSV) prophylaxis for sub-
groups (eg, those with cardiac disease), additional immunizations 
and longer treatment courses. However, no previous systematic 
review has been undertaken to ascertain the evidence base.
The aim of this study is to systematically review the litera-
ture on the management of RTIs in this vulnerable group to identify 
which strategies work best.
METHODS
Search Strategy
We developed a broad search strategy combining the terms 
Down’s Syndrome, Respiratory Tract Infections and relevant syno-
nyms. To increase the yield of potential relevant articles, management 
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options for Down’s syndrome-related comorbidities such as sleep-
disordered breathing, chronic lung disease and congenital heart dis-
ease were also included in the syntax. To obtain a broad overview 
of the existing evidence base, we did not limit our search strategy 
to specific study types, language or publication date (Appendix 1).
Information Sources
We searched the following electronic databases from their 
inception up to February 2015: PubMed, EMBASE, CINAHL 
and Cochrane Library. Trial registries such as WHO ICTRP and 
ClinicalTrials.gov were also searched for completed or ongoing 
studies. To identify any additional studies, reference lists of all 
included articles and relevant systematic reviews were screened.
We searched gray literature through web searches via 
Google Scholar, SIGLE and relevant research websites [includ-
ing National Institute for Health Research (NIHR), Wellcome 
Trust and Medical Research Council]. Contact with research 
networks and charities were also made (including Trisomy 21 
Research Society,11 Down’s Syndrome Association,12 Downs 
Syndrome International,13 Down’s Heart Group14 and Downs 
Syndrome Medical Interest Group United Kingdom and Ire-
land).15
Eligibility Criteria
We included studies of individuals with Down’s syndrome 
irrespective of age and covering any intervention (ie, medical 
and/or surgical) for the prevention or treatment of RTIs includ-
ing watchful waiting and supportive care. We anticipated that 
the number of randomized controlled trials (RCTs) for this topic 
would be limited because of the specific study population. There-
fore, we included all study types except for case series and case 
reports.
Study Selection and Inclusion
Two review authors (L.M. and K.R.) independently 
screened titles and abstracts retrieved from the database searches 
along with the reference lists of the included studies and relevant 
systematic reviews. The same authors independently reviewed the 
full text of potentially relevant studies against the predefined eli-
gibility criteria. A third author (R.V.) reviewed the discrepancies, 
and differences were resolved by consensus. Data extraction was 
performed by 1 reviewer (K.R.) and was independently checked 
by 2 reviewers (L.M. and R.V.). Two reviewers (L.M. and R.V.) 
independently performed the quality assessment of included stud-
ies.
Outcomes of Interest
As our systematic review aimed to identify interventions 
to either prevent or treat RTIs, identified papers were likely to 
encompass a broad range of outcome measures. As a conse-
quence, we did not pre-specify any detailed outcome measures. 
We looked specifically at impact on frequency and recurrence of 
RTIs and any documented adverse effects.
Data Extraction
Data were extracted using a standardized form including 
information on study characteristics, setting, design, randomiza-
tion, inclusion and exclusion criteria, data-analysis methods, inter-
ventions, outcomes and results.
Risk of Bias Assessment
We measured risk of bias in RCTs and non-randomized 
studies using the relevant “Risk of Bias” tools developed by 
Cochrane.16,17 We excluded studies with a critical risk of bias from 
our analyses.
FIGURE 1. Flow diagram of search results 
and selecting studies for inclusion.
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Assessment of Heterogeneity
We assessed clinical heterogeneity across the included 
studies by reviewing differences in populations, interventions 
and outcomes measured. In view of the marked differences in the 
interventions used in the individual studies, we did not perform a 
meta-analysis.
Role of the Funding Source
This article presents independent research funded through a 
PhD fellowship awarded to the first author by the NIHR. The views 
expressed are those of the authors and not necessarily those of the 
NIHR.
RESULTS
Study Selection
Our searches identified 13,575 articles. After screening 
of titles and abstracts, 157 potentially relevant published arti-
cles were identified. After reviewing the full texts, 5 published 
studies were deemed suitable for inclusion (Fig. 1).18–22 An addi-
tional unpublished ongoing study was identified through our 
searches.23
Study Characteristics
The main characteristics of the 5 published studies are pre-
sented in Table 1. All studies evaluated preventative interventions 
against RTI in children with Down’s syndrome: 2 studies assessed 
the effectiveness of passive immunotherapy, with palivizumab and 
pidotimod, respectively18,19; 2 studies looked at prophylactic treat-
ment with oral zinc supplements20,22 and 1 study at the effects of a 
school-based infection-control program.21
All studies exclusively studied children with Down’s syn-
drome. The studies varied in terms of design (1 RCT, 1 non-RCT, 
1 cohort study and 2 controlled before-after studies), age range of 
included children and duration of follow-up (Table 1). Two stud-
ies were conducted in Italy,19,22 1 in Canada,20 1 in Canada and the 
Netherlands18 and 1 in the United States.21
We identified 1 postmarketing observational study ongo-
ing in Japan, looking at the effects of palivizumab in preventing 
lower RTIs caused by RSV in children under the age of 2 who are 
either immunocompromised or who have Down’s syndrome.23
Risk of Bias Across Studies
The overall risk of bias of the RCT was moderate (Table 2). 
The overall risk of bias of the non-randomized studies was mod-
erate for the cohort study20 (although high quality, there was 
no controlled comparator arm) and serious for the non-RCT.19 
For the 2 controlled before-after studies, risk of bias was noted 
to be critical, and they were therefore excluded from analyses 
(Table 3).21,22
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TABLE 2. Risk of Bias Assessment for Lockitch et al20 
Using the Cochrane Risk of Bias Tool 3
Domain Judgment
Random sequence generation (selection bias) Unclear risk
Allocation concealment (selection bias) Unclear risk
Blinding of participants and personnel (performance 
bias)
Low risk
Blinding of outcome assessment (detection bias) Low risk
Incomplete outcome data addressed (attrition bias) High risk
Selective reporting (reporting bias) Unclear risk
Other bias Unclear risk
Overall Moderate risk
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Results of Individual Studies
Zinc Therapy
Lockitch et al randomized 64 children with Down’s syn-
drome to oral zinc therapy for 6 months or placebo, but reported 
only on the 50 children (23 treated with zinc and 27 with placebo) 
who had extreme numbers (ie, exceeding the 90th percentile value 
for siblings and age-matched unrelated children).
In this subset of children with Down’s syndrome, during 
6 months of treatment, no significant differences in terms of upper 
RTI episodes, doctor consultations and antibiotic use were found 
between children receiving zinc and children receiving placebo.20
Pidotimod
In a non-RCT, La Mantia et al followed 26 children with 
Down’s syndrome who had experienced at least 6 upper RTIs in the 
preceding 6 months and who received either the immunostimulant 
pidotimod for 3 months (14 children) or no treatment (12 children). 
While on pidotimod treatment, children with Down’s syndrome had 
fewer parent-reported upper RTI recurrences [mean 2.7, standard 
deviation (SD) 1.1 vs. mean 6.8, SD 1.3] and days with fever (mean 
4.5, SD 3.5 vs. mean 16.9, SD 6.7) compared with those not receiving 
this treatment.19
Palivizumab
In a prospective cohort study, Yi et al followed 532 Canadian 
children with Down’s syndrome treated with the palivizumab for 2 
RSV seasons and 233 Dutch children with Down’s syndrome who 
did not receive this immunostimulant. In the first 2 years of life, 
treatment with palivizumab resulted in a 3.6-fold reduction in the 
incidence rate ratio (adjusted incidence rate ratio 3.63, 95% confi-
dence interval: 1.52–8.67) of RSV-RTI hospitalizations. Treatment, 
however, did not reduce overall hospitalizations for RTI (adjusted 
incidence rate ratio 1.11, 95% confidence interval: 0.80–1.55).18
DISCUSSION
By a broad systematic search and review of the literature, we 
identified only 5 published studies on the management of RTIs in 
children with Down’s syndrome. This is remarkable in the light of 
the large body of literature in this field: Most high-quality studies 
on the management on RTIs in children have excluded this vulner-
able group that are at high risk of these infections.
We found that pidotimod, an immunostimulant, and palivi-
zumab, a human monoclonal antibody, may have a role in preventing 
RTIs in children with Down’s syndrome with the latter particularly 
effective in young children (until 2 years of age) against RSV-RTI 
hospitalizations. Currently, the American Academy of Pediatrics rec-
ommends the use of palivizumab in children with Down’s syndrome 
who are at risk of severe RSV-related infections (eg, congenital heart 
disease, airway clearance issues, prematurity).24 Once published, the 
ongoing postmarketing observational study is likely to add to this 
evidence base. Oral zinc was not noted to be effective in preventing 
RTIs.
The evidence base for RTI management in people with Down’s 
syndrome is incomplete, with only a limited number of moderate to 
serious risk of bias studies available on the prevention of RTIs in chil-
dren. As such, clinical management of RTIs in this vulnerable group is 
currently guided by studies including either no or only limited number 
of children with Down’s syndrome. Methodologically rigorous studies 
are warranted to guide clinicians on how best to prevent and treat RTIs 
in children with Down’s syndrome.
APPENDIX 1. DOwN’S SYNDROME TERMS
MeSH: “Down Syndrome” OR TiAB: Down* syndrome* 
OR mongolism OR trisomy 21 OR aneuploidy OR down* disease* 
OR mongoloid idiocy OR Trisomy G AND
INFECTION TERMS
MeSH: Respiratory tract diseases OR Otitis media OR 
Respiratory syncytial virus, human OR Empyema OR TiAB: 
respiratory tract infection* OR upper respiratory infection* OR 
lower respiratory infection* OR RTI OR URTI OR LRTI OR rhi-
nitis OR common cold* OR head cold* OR sinusitis OR rhinosi-
nusitis OR pharyngitis OR laryngitis OR tracheitis OR tonsillitis 
OR sore throat* OR croup OR epiglottitis OR otitis media OR 
AOM OR OME OR glue ear OR ear discharge OR otorrhoea 
OR otorrhea OR bronchitis OR bronchopneumonia OR pneumo-
nia OR cough* OR bronchiolitis OR respiratory syncytial virus 
OR RSV or empyema OR influenza* OR lung abscess* OR pul-
monary tract infection* respiration tract infection* OR human 
flu OR pulmonary abscess* OR Nasal Catarrh* OR middle ear 
inflammation* OR bronchial pneumonia* OR lung inflamma-
tion* OR
ASSOCIATED CONDITION TERMS
MeSH: cardiovascular diseases OR TiAB: respiratory tract 
disease* OR lung disease* OR cardiovascular disease* or obstruc-
tive sleep apnea* or pleural cyst* or congenital heart disease* or 
atrioventricular canal defect* or atrial septal defect* or ventricular 
septal defect* or patent ductus arteriosus or tetralogy of fallot OR 
double outlet right ventricle or mitral valve prolapse or aortic regur-
gitation or acquired valve disease* or OSAHS OR fallot* tetralogy 
or AVC defect* or heart atrium septum defect or heart ventricle 
septum defect or floppy mitral valve* or aortic incompetence or 
aortic valve insufficiency or heart valve disease*
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